Biogen (BIIB), it’s your turn.
I’m speaking of an acquisition, of course. The $9 billion purchase of Juno Therapeutics by Celgene announced Monday, which followed Gilead Sciences’s nearly $12 billion acquisition of Kite Pharma last year, shifts the M&A spotlight to Cambridge-based Biogen.
About the Author Reprints
http://alph.st/ba1df6ff Celgene after making two (Impact and Juno) multi-billion dollar acquisitions this year, reports results that beat the estimates for the fourth quarter of 2017